BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.

Adepitan A OwoshoAdeola M LadejiKehinde E AdebiyiMofoluwaso A OlajideIkechukwu S I OkoyeTemitope KehindeNgozi N NwizuKurt F Summersgill

Published in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2020)

BRAF V600E mutation preferentially occurs in mandibular ameloblastomas, especially in non-plexiform ameloblastomas. These patients may benefit therapeutically from the use of BRAF inhibitors.

Keyphrases

end stage renal disease
metastatic colorectal cancer
newly diagnosed
ejection fraction
chronic kidney disease
wild type
prognostic factors
peritoneal dialysis